R R

What Is Revlimid?

Revlimid is a prescription medication containing lenalidomide, an immunomodulatory drug related to thalidomide. It is used to treat selected blood cancers and bone marrow disorders, including multiple myeloma, certain myelodysplastic syndromes, and specified lymphomas. Revlimid is available as oral capsules, with dosing schedules that depend on the diagnosis and accompanying medications. It affects immune activity and pathways involved in the growth and survival of abnormal cells. Revlimid carries boxed warnings for severe birth defects, reduced blood cell counts, and blood clots. It is distributed through a restricted Risk Evaluation and Mitigation Strategy program.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Revlimid?

Revlimid is a prescription medication containing lenalidomide, an immunomodulatory drug related to thalidomide. It is used to treat selected blood cancers and bone marrow disorders, including multiple myeloma, certain myelodysplastic syndromes, and specified lymphomas. Revlimid is available as oral capsules, with dosing schedules that depend on the diagnosis and accompanying medications. It affects immune activity and pathways involved in the growth and survival of abnormal cells. Revlimid carries boxed warnings for severe birth defects, reduced blood cell counts, and blood clots. It is distributed through a restricted Risk Evaluation and Mitigation Strategy program.

read more about revlimid ...

Copy this HTML:

Copy HTML Copied!

How Does Revlimid Work?

Revlimid binds to cereblon, a component of an enzyme complex involved in regulating the degradation of certain proteins. This changes the breakdown of proteins associated with cell growth and immune activity. Lenalidomide has effects on malignant blood cells and the surrounding bone marrow environment and can alter the activity of certain immune cells. These combined actions contribute to its usefulness in selected blood cancers and bone marrow disorders. Its effects depend on the diagnosis and combination treatment regimen. Because lenalidomide also influences normal blood cell production, patients can develop significant decreases in neutrophils and platelets during treatment.

What Conditions Does Revlimid Treat?

Revlimid is approved for multiple myeloma in adults when combined with dexamethasone and as maintenance treatment after autologous stem cell transplantation. It also treats transfusion-dependent anemia associated with lower-risk myelodysplastic syndromes involving a deletion 5q chromosomal abnormality. Additional indications include mantle cell lymphoma that has progressed after at least two prior therapies, including bortezomib, and previously treated follicular or marginal zone lymphoma when combined with a rituximab product. Revlimid is not recommended for chronic lymphocytic leukemia outside controlled clinical trials. A hematologist or oncologist determines eligibility using the diagnosis, treatment history, blood counts, and kidney function.

How Should Revlimid Be Taken?

Revlimid is taken orally according to an indication-specific schedule. For multiple myeloma with dexamethasone, a common starting regimen is 25 mg once daily on days one through 21 of each 28-day cycle. Maintenance after autologous stem cell transplantation commonly begins at 10 mg daily on days one through 28. For deletion 5q-associated myelodysplastic syndromes, the usual starting dose is 10 mg once daily. Lymphoma regimens differ and may include treatment for 21 days followed by seven days without the medication. Capsules must be swallowed whole, and kidney impairment requires dose adjustments. Pregnancy prevention requirements and regular blood count monitoring are mandatory.

What Are the Side Effects and Warnings of Revlimid?

Common adverse effects include fatigue, diarrhea, constipation, nausea, rash, and reduced blood cell counts. Revlimid carries boxed warnings for embryo-fetal toxicity, severe neutropenia and thrombocytopenia, and increased risk of venous and arterial blood clots. Exposure during pregnancy can cause severe birth defects or fetal death. Other serious risks include infections, liver injury, severe skin reactions, secondary primary malignancies, and tumor lysis syndrome. Patients require regular blood counts and follow all pregnancy testing and contraception requirements under the Lenalidomide REMS program. Fever, unusual bruising, chest pain, shortness of breath, or severe rash requires prompt medical assessment.

Common Questions About Revlimid

Is Revlimid the same as lenalidomide?

Yes. Revlimid is the brand name for lenalidomide, an immunomodulatory medication used for selected blood cancers and bone marrow disorders.

Can Revlimid treat multiple myeloma?

Yes. Revlimid is approved with dexamethasone for adults with multiple myeloma and as maintenance treatment after autologous stem cell transplantation.

Why does Revlimid require a REMS program?

Revlimid can cause severe birth defects or fetal death. Its restricted distribution program includes pregnancy prevention, counseling, and other safety requirements.

Can Revlimid cause blood clots?

Yes. Revlimid increases the risk of deep vein thrombosis, pulmonary embolism, heart attack, and stroke in certain treatment settings. Patients may need preventive measures determined by their clinician.

References

DailyMed - REVLIMID (lenalidomide) capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be. Date Accessed November 3, 2026.

Lenalidomide. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK583703/. Date Accessed November 3, 2026.

Lenalidomide. MedlinePlus. https://medlineplus.gov/druginfo/meds/a608001.html. Date Accessed November 3, 2026.

Lenalidomide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/216326. Date Accessed November 3, 2026.

Revlimid. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid. Date Accessed November 3, 2026.